1. Berry SJ, Coffey DS, Walsh PC, Ewing LL . The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–479.
2. Rosen R et al. LUTS and male sexual dysfunction: the Multi-national Survey of the Aging Male (MSAM-7) [abstract 500161]. American Urological Association Annual Meeting, Orlando, FL, May 26, 2002.
3. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, the ALGEBI Study Group. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 190–198.
4. Chapple CR et al, on behalf of the European Tamsulosin Study Group. Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155–167.
5. Dutkiewics S . Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 2001; 32: 423–432.